If authorized, Pfizer said it would supply the drug beginning later
this year and concluding in 2022.
"This promising treatment could help accelerate our path out of this
pandemic by offering another life-saving tool for people who get
sick with COVID-19," said Xavier Becerra, secretary of the United
States Department of Health and Human Services.
(Reporting by Manas Mishra in Bengaluru; Editing by Ramakrishnan M.)
[to top of second column] |
![](http://archives.lincolndailynews.com/2021/Nov/18/images/ads/current/atlantabank_lda_SFARM_2019.png)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |